Open access
3,548
Views
7
CrossRef citations to date
0
Altmetric
Research Paper
Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in Germany
Desmond Currana Value Evidence, GSK, Wavre, BelgiumCorrespondence[email protected]
https://orcid.org/0000-0002-7423-0111View further author information
Desirée Van Oorschota Value Evidence, GSK, Wavre, Belgium
https://orcid.org/0000-0002-0382-0333View further author information
Sean Matthewsb Value Evidence Freelance c/o GSK, Wavre, Belgium
https://orcid.org/0000-0001-7427-7326View further author information
Johannes Hainc Vaccines, GSK, München, GermanyView further author information
, Ahmed Ehab Salema Value Evidence, GSK, Wavre, Belgium
https://orcid.org/0000-0003-0704-8085View further author information
Magdalena Schwarzc Vaccines, GSK, München, Germany
https://orcid.org/0000-0002-4850-8597View further author information
Pages 5296-5303
|
Received 03 Aug 2021, Accepted 01 Nov 2021, Published online: 14 Dec 2021
Reprints and Permissions
This is an open access article distributed under the terms of the Creative Commons CC BY license, which permits unrestricted use, distribution, reproduction in any medium, provided the original work is properly cited.
You are not required to obtain permission to reuse this article in part or whole.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.